Table 2. Comparison of laboratory parameters and ocular parameters in subjects with PACG, stratified according to severity.
Factors | Mild PACG, n= 183 | Moderate PACG, n= 174 | Severe PACG, n= 375 | P value |
---|---|---|---|---|
Age, years | 63.36±7.97 | 65.11±9.837 | 63.58±10.99 | 0.178 |
Gender (Male/Female) | 62/121 | 53/121 | 141/234 | 0.248 |
IOP (mm Hg) | 27.90±10.20 | 27.17±9.31 | 34.92±13.10 | <0.001a,c |
VCDR | 0.45±0.17 | 0.50±0.20 | 0.72±0.24 | <0.001a,b,c |
CCT (μm) | 539.11±39.16 | 549.55±61.35 | 549.62±46.49 | 0.108 |
ACD (mm) | 1.85±0.36 | 1.85±0.44 | 1.87±0.76 | 0.893 |
AL (mm) | 22.31±0.97 | 22.33±1.02 | 22.50±1.50 | 0.223 |
MD (dB) | 3.335±1.61 | 8.73±1.83 | 21.70±5.61 | <0.001a,b,c |
MS (dB) | 22.06±5.15 | 18.12±2.33 | 6.94±5.32 | <0.001a,b,c |
WBC (109/L) | 5.87±1.76 | 6.03±1.63 | 6.38±2.01 | 0.006a,c |
platelet (109/L) | 194.39±53.76 | 207.50±57.74 | 194.91±56.82 | 0.033b,c |
Neutrophil (109/L) | 3.81±1.43 | 3.95±1.21 | 4.25±1.68 | 0.003a,c |
Lymphocyte (109/L) | 1.56±0.46 | 1.59±0.55 | 1.56±0.52 | 0.780 |
Monocyte (109/L) | 0.38±0.14 | 0.39±0.13 | 0.40±0.16 | 0.219 |
NLR | 2.58±1.09 | 2.62±0.87 | 2.98±1.55 | 0.001a,c |
PLR | 132.28±45.23 | 148.21±120.54 | 135.81±57.95 | 0.103 |
LMR | 4.40±1.52 | 4.42±1.55 | 4.26±1.81 | 0.485 |
Abbreviations: IOP: intraocular pressure, VCDR: vertical cup-disc ratio, CCT: central corneal thickness, AL: axial length, ACD: anterior chamber depth, MD: visual fields mean deviation, MS: visual fields mean sensitivity, PACG: primary angle closure glaucoma. WBC: white blood cells. NLR: neutrophil-to-lymphocyte ratio. PLR: platelet-to-lymphocyte ratio. LMR: lymphocyte-to-monocyte ratio. Data are expressed as mean± standard deviation (SD). Chi-square test and One-way ANOVA was used.
aP<0.05 for the difference between Mild PACG and Severe PACG (1-way ANOVA with the LSD post hoc test).
bP<0.05 for the difference between Mild PACG and Moderate PACG (1-way ANOVA with the LSD post hoc test).
cP<0.05 for the difference between Moderate PACG and Severe PACG (1-way ANOVA with the LSD post hoc test).